Announcement
MyHealthChecked PLC : Launch of COVID-19 rapid antigen test service
RNS Number : 3344T
MyHealthChecked PLC
24 November 2021
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Launch of COVID-19 Day 2 rapid antigen test and verification service
MyHealthChecked Plc (AIM: MHC), announces the launch of two home testing services for travellers entering and departing the UK. On 24 November the company will begin selling a rapid antigen test and a verification service for residents and vaccinated travellers arriving in England from a non-red list country, followed by a Fit to Fly rapid test for travellers leaving the UK launching next week.
The online service will allow customers to order a test before arriving into England (where COVID-19 travel rules are different to those in Scotland, Wales and Northern Ireland) or departing from the UK. The test can be taken at home with results verified by a trained professional within 2 hours of completing the test. Customers are then notified by email when the result is ready, and a QR-code secured COVID-19 result certificate is made available for download.
The service will utilise the CE approved, ISO certified and UK Government validated FlowFlex® Rapid Test Kit, a lateral flow test that is easy to administer via a simple nasal swab, which provides results in 15 minutes and offers 98.8% accuracy.
MyHealthChecked has also partnered with medical specialists Mediskills, who will provide fully trained NHS professionals to verify test results as part of this service. MyHealthChecked will have full responsibility for overseeing the service, processing orders and dispatches, as well as warehousing test kit stock. The Company will continue to maintain the high standards of customer service already being delivered across its other testing services.
MyHealthChecked remains a high-quality laboratory provider but has adapted to evolving market requirements, allowing the Company's reputation for delivering a good customer experience and a reliable testing service across a wider variety of testing formats.
Penny McCormick, Chief Executive Officer of MyHealthChecked PLC , commented: "I am delighted to announce the launch our new COVID-19 Day 2 rapid antigen testing service. Our agility in adapting to the changing market needs shows the strength of our team, our digital platform, and our ability to offer customers highly compliant testing services via on a digital platform that gives a great user experience. Our focus on ensuring the best possible customer service has already allowed us to meet the needs of our key retail partners and has established a trusted relationship based on the best possible service delivery."
|
MyHealthChecked PLC |
||
|
P enny McCormick , Chief Executive Officer |
via Walbrook PR |
|
|
Gareth Davies, Chief Financial and Operations Officer |
|
|
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
|
Neil Baldwin |
|
|
|
|
|
|
|
Oberon Capital Ltd (Broker) |
Tel: +44 (0)203 179 5344 |
|
|
Mike Seabrook |
||
|
|
|
|
|
Walbrook PR Ltd (Media & IR) |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: +44(0)7980 541 893 / +44 (0)7407 804 654 |
|
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests. MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online and would be viable for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market, with a focus on accessibility at the right price, led by UK-based experts.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFLFLTLILVFIL
;